{
    "nct_id": "NCT03063619",
    "official_title": "A Randomized, Double-Blind, Placebo-Controlled Study of 4-hydroxytamoxifen Topical Gel in Women With Mammographically Dense Breast",
    "inclusion_criteria": "* Women age 40-69 years, or less than 40 years if 5-year breast cancer Gail risk is ≥ 1.66%.\n* Mammographically dense breast (heterogeneously dense [C] or extremely dense [D], based on American College of Radiology [ACR] BIRADS fifth edition classification or heterogeneously dense [3] or extremely dense [4], based on ACR BIRADS fourth edition classification) in either breast\n* Eastern Cooperative Oncology Group (ECOG) performance status =< 1 (Karnofsky >= 70%)\n* White blood cells >= 3,000/microliter\n* Absolute neutrophil count >= 1,500/microliter\n* Platelets >= 100,000/microliter\n* Total bilirubin within normal institutional limits\n* Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 1.5 × institutional upper limit of normal (ULN)\n* Creatinine within normal institutional limits\n* Participant must have a gynecology examination within the last 3 years, with no atypical hyperplasia and no cancer\n* Premenopausal women taking non hormonal intra-uterine device (IUD) birth control method will be eligible, if they have been on the same IUD for at least 3 months prior to enrollment and plan to continue using the same method throughout the study\n* Women of child-bearing potential must agree to use a reliable nonhormonal contraceptive method during the study and for 2 months after completing study medications; reliable nonhormonal methods of contraception include barrier contraception and an intra-uterine device (IUD); Note: women who had tubal ligation or had a partner who had undergone a vasectomy (and are monogamous) are eligible for the study and are not required to use barrier contraception\n* If the participant is of childbearing potential, she must have a documented negative urine pregnancy test within 7 days prior to randomization\n* Willingness to avoid exposing breast skin to natural or artificial sunlight (i.e. tanning beds) for the duration of the study\n* Ability to understand and the willingness to sign a written informed consent document\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 40 Years\nMust have maximum age of 69 Years",
    "exclusion_criteria": "* History of allergic reactions attributed to compounds of similar chemical or biologic composition to 4-OHT gel\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, thromboembolic disease, or psychiatric illness/social situations that would limit compliance with study requirements\n* Pregnant, or had given birth, or nursed at any time during the last 12 months\n* Women with a previous history of invasive breast cancer or bilateral ductal carcinoma in situ (DCIS) or current untreated DCIS; women with a history of cancer within the last 3 years, except for non-melanoma skin cancer; women with unilateral DCIS (with or without radiation therapy) are eligible as long as they have an unaffected breast\n* Prior bilateral breast surgery (mastectomy, segmental mastectomy, or breast augmentation surgery including breast implants or breast reductions)\n* Women with \"mosaic mammographic screening views\", i.e., whose larger breast size precludes being imaged within a single mammographic screening view\n* Women with active liver disease, abnormal uterine bleeding, or prior diagnosis of endometrial hyperplasia\n* Prior use of selective estrogen receptor modulators (SERMS) and aromatase inhibitors (AIs) for prevention or therapy\n* Skin lesions on the breast that disrupt the stratum corneum (e.g., eczema, ulceration)\n* Treatment with any investigational drug or investigational biologic within 30 days of initiating study treatment or during the study",
    "miscellaneous_criteria": ""
}